A randomized double-blind, placebo-controlled, crossover, dose escalation study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK704838 and tiotropium bromide.

Trial Profile

A randomized double-blind, placebo-controlled, crossover, dose escalation study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK704838 and tiotropium bromide.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs GSK 704838 (Primary) ; Tiotropium bromide
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Oct 2008 Actual end date changed from Jan 2008 to Feb 2008 as reported by Clinicaltrials.gov.
    • 15 Oct 2008 Actual start date changed from Oct 2007 to Sep 2007 as reported by Clinicaltrials.gov.
    • 21 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top